Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors
| Autor: | Teipel, Sj, Cavedo, E, Hampel, H, Grothe, Mj, Aguilar, Lf, Babiloni, C, Baldacci, F, Benda, N, Black, Kl, Bokde, Alw, Bonuccelli, U, Broich, K, Bun, Rs, Cacciola, F, Castrillo, J, Ceravolo, R, Chiesa, Pa, Colliot, O, Coman, C, Corvol, J, Cuello, Ac, Depypere, H, Dubois, B, Duggento, A, Durrleman, S, Escott-Price, V, Federoff, H, Ferretti, Mt, Fiandaca, M, Frank, Ra, Garaci, F, Genthon, R, George, N, Giorgi, Fs, Graziani, M, Haberkamp, M, Habert, M, Herholz, K, Karran, E, Kim, Sh, Koronyo, Y, Koronyo-Hamaoui, M, Lamari, F, Langevin, T, Lehericy, S, Lista, S, Lorenceau, J, Mapstone, M, Neri, C, Nistico, R, Nyasse-Messene, F, O'Bryant, Se, Perry, G, Ritchie, C, Rojkova, K, Rossi, S, Saidi, A, Santarnecchi, E, Schneider, Ls, Sporns, O, Toschi, N, Verdooner, Sr, Vergallo, A, Villain, N, Welikovitch, La, Woodcock, J, Younesi, E, Cummings, Jl |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Aging
hippocampus Hippocampus Neurodegenerative Alzheimer's Disease lcsh:RC346-429 cholinergic treatment memory 0302 clinical medicine Medicine and Health Sciences Psychology Medicine Cognitive decline Episodic memory basal forebrain Original Research Basal forebrain Settore FIS/07 05 social sciences Cognition IMPAIRMENT Manchester Institute for Collaborative Research on Ageing Neurology Neurological Cohort DONEPEZIL Cardiology NUCLEUS BASALIS ADAS-COG MRI CHOLINERGIC SYSTEM medicine.medical_specialty ResearchInstitutes_Networks_Beacons/MICRA Clinical Sciences COMPOSITE SCORE ATROPHY 050105 experimental psychology 03 medical and health sciences Clinical Research Internal medicine Behavioral and Social Science Acquired Cognitive Impairment Dementia 0501 psychology and cognitive sciences ddc:610 lcsh:Neurology. Diseases of the nervous system business.industry Alzheimer's Disease Neuroimaging Initiative Neurosciences Alzheimer Precision Medicine Initiative Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) prediction medicine.disease NEUROIMAGING INITIATIVE ADNI Brain Disorders SUBSTANTIA INNOMINATA executive function Cholinergic treatment Executive function Memory Prediction Cholinergic Neurology (clinical) business 030217 neurology & neurosurgery |
| Zdroj: | FRONTIERS IN NEUROLOGY Frontiers in neurology 9, 642 (2018). doi:10.3389/fneur.2018.00642 Frontiers in Neurology Alzheimer's Disease Neuroimaging Initiative & Alzheimer Precision Medicine Initiative (APMI) 2018, ' Basal forebrain volume, but not hippocampal volume, is a predictor of global cognitive decline in patients with alzheimer's disease treated with cholinesterase inhibitors ', Frontiers in Neurology, vol. 9, no. AUG, 642 . https://doi.org/10.3389/fneur.2018.00642 Frontiers in Neurology, Vol 9 (2018) Frontiers in neurology, vol 9, iss AUG |
| ISSN: | 1664-2295 |
| Popis: | Background: Predicting the progression of cognitive decline in Alzheimer's disease (AD) is important for treatment selection and patient counseling. Structural MRI markers such as hippocampus or basal forebrain volumes might represent useful instruments for the prediction of cognitive decline. The primary objective was to determine the predictive value of hippocampus and basal forebrain volumes for global and domain specific cognitive decline in AD dementia during cholinergic treatment.Methods: We used MRI and cognitive data from 124 patients with the clinical diagnosis of AD dementia, derived from the ADNI-1 cohort, who were on standard of care cholinesterase inhibitor treatment during a follow-up period between 0.4 and 3.1 years. We used linear mixed effects models with cognitive function as outcome to assess the main effects as well as two-way interactions between baseline volumes and time controlling for age, sex, and total intracranial volume. This model accounts for individual variation in follow-up times.Results: Basal forebrain volume, but not hippocampus volume, was a significant predictor of rates of global cognitive decline. Larger volumes were associated with smaller rates of cognitive decline. Left hippocampus volume had a modest association with rates of episodic memory decline. Baseline performance in global cognition and memory was significantly associated with hippocampus and basal forebrain volumes; in addition, basal forebrain volume was associated with baseline performance in executive function.Conclusions: Our findings indicate that in AD dementia patients, basal forebrain volume may be a useful marker to predict subsequent cognitive decline during cholinergic treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|